Does TRT Cause Prostate Cancer? What 80 Years of Research Actually Shows

The story starts in 1941, when a researcher named Charles Huggins took men who had already been castrated and had advanced prostate cancer, gave them testosterone injections, and watched their cancer markers rise. He also showed that castration caused those markers to fall. From that observation, the medical community drew a straight line: if removing testosterone helps, then adding it must cause harm. Huggins won the Nobel Prize in 1966, and that logic has been shaping prostate cancer fears ever since.

The logic is not entirely wrong. Testosterone does feed prostate tissue. That part is true. What the 1941 experiment could not tell anyone is whether that relationship holds across the entire range of testosterone levels, or only at the very bottom of that range. And that distinction turns out to be everything.

Here is the full picture before zooming in on any mechanism. The prostate depends on androgens to function. When testosterone drops very low, prostate tissue shrinks. When testosterone rises from very low back toward normal, prostate tissue responds and markers like PSA climb. That response looks alarming if you only watch the bottom of the curve. But the curve does not keep climbing forever. It flattens out. And understanding where it flattens out is the whole key to understanding why decades of fear around TRT and prostate cancer do not hold up.

That flattening happens through something called receptor saturation, which is the point at which all the androgen receptors in the prostate are already occupied and adding more testosterone produces no additional effect. Think of it like a parking lot. When the lot is empty, every car that arrives finds a spot and the response is dramatic. When the lot is full, more cars circling the block change nothing for the cars already parked inside.

Research by Morgentaler and Traish, published in the European Urology journal in 2009, mapped out where that saturation point sits. The prostate's androgen receptors reach full occupancy at approximately 240 to 250 nanograms per deciliter of serum testosterone, which is a level at the very low end of the normal male range and well below where the average healthy man, let alone a man on TRT, typically sits. Below that threshold, changes in testosterone have a dramatic effect on prostate tissue. Above it, the response essentially plateaus and adding more testosterone changes very little in terms of prostate stimulation.

This is what Huggins was actually measuring in 1941 without knowing it. His patients had been castrated, which drove their testosterone to near zero and sat them far below the saturation point. When he injected testosterone into those men, he was moving them from the steep part of the curve, and of course the prostate responded. The error was in extrapolating that finding upward and concluding that men already operating above the saturation threshold, meaning essentially all men with normal testosterone or men on TRT, would face the same proportional risk.

The research that followed once people started testing that assumption directly does not support the original fear.

The largest clinical trial on this question tracked 5,204 men with hypogonadism across 33 months, randomizing them to either testosterone replacement therapy or placebo. Prostate cancer developed in 0.46 percent of the TRT group and 0.42 percent of the placebo group, producing a hazard ratio of 1.07 with a p-value of 0.87, which means the difference observed was statistically indistinguishable from random noise. A population study out of Finland followed 78,615 men over 18 years and found that prostate cancer specific mortality was actually lower in TRT users, with a hazard ratio of 0.52, meaning TRT users were roughly half as likely to die of prostate cancer as the comparison group. A 2024 meta-analysis pulling together 28 randomized controlled trials found that PSA, the blood marker most commonly used to track prostate health, rose by an average of 0.08 nanograms per milliliter in men on TRT, and that the International Prostate Symptom Score, which measures urinary symptoms, changed by exactly zero.

The study that probably does the most to put the original fear to rest goes further than any of those. Researchers looked at 69,984 men who had already been treated for localized prostate cancer, and within that group identified 1,012 men who received testosterone therapy after their treatment. They found no increase in cancer recurrence and no increase in death compared to men who did not receive TRT. The logic here matters as much as the number. If testosterone were truly a driver of prostate cancer growth in men with normal or elevated levels, you would expect it to be especially dangerous in men who already had cancer cells present. That is the highest-risk scenario you could construct, and even there, no signal appeared.

All of that brings the practical question down to monitoring, not avoidance.

The Endocrine Society's clinical practice guideline recommends getting a baseline PSA before starting TRT so you have a reference point, then rechecking at three to six months, and then annually after that. The threshold that should prompt a conversation with a urologist is a PSA increase of more than 1.4 nanograms per milliliter above your individual baseline, not above a population average, but above your own starting number.

That structure matters because some PSA rise is normal when you start TRT, particularly if you were hypogonadal before, because the prostate was operating below the saturation point and is now being adequately stimulated for the first time. What you are watching for is a rise that continues beyond what the saturation model would predict, which is the kind of persistent climb that warrants investigation regardless of whether you are on TRT.

The fear that has kept men off testosterone replacement for decades did not come from population data, from randomized trials, or from studies in men with existing cancer. It came from a 1941 experiment in castrated men with metastatic disease, which is a condition so far from the clinical context of TRT that the comparison barely holds. The saturation model explains why those two situations behave differently, and eighty years of subsequent research has confirmed it.

Testosterone does not exist on a simple scale where more always means more danger. At the very bottom, biology is sensitive to changes. Above a relatively modest threshold, the relationship changes entirely. The 1941 data was real. The conclusion drawn from it was not.

---

References

1. Huggins CV, Hodges CV. 1941. "Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate." Cancer Research. 14:293-297. Finding: Castration reduced acid phosphatase in men with metastatic prostate cancer; testosterone injection into castrated men raised it back. Source
2. Morgentaler A, Traish AM. 2009. "Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth." European Urology. 552:310-320. Finding: Prostate androgen receptors saturate at approximately 240-250 ng/dL; above this threshold, additional testosterone produces minimal prostate effect. Source
3. Bhasin S, Travison TG, Pencina KM, et al. 2023. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial." JAMA Network Open. 612:e2348692. Finding: 5,204 men, 33 months. Prostate cancer: 0.46% TRT vs 0.42% placebo HR 1.07, p=0.87. No significant difference. Source
4. Siltari A, Murtola TJ, Kausz J, et al. 2023. "Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men." Acta Oncologica. 6211-12:1755-1762. Finding: 78,615 men, 18-year follow-up. Prostate cancer-specific mortality LOWER in TRT users HR 0.52. Source
5. Xu Z, Chen X, Zhou H, et al. 2024. "An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate." Frontiers in Endocrinology. 15:1335146. Finding: 28 RCTs. PSA change: 0.08 ng/mL not significant. IPSS change: 0.00 literally zero difference. Source
6. Sarkar RR, Patel SH, Parsons JK, et al. 2021. "Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease." Prostate Cancer and Prostatic Diseases. 24:739-746. Finding: 69,984 men with treated prostate cancer, 1,012 received TRT. No increase in recurrence or death. Source
7. Bhasin S, Brito JP, Cunningham GR, et al. 2018. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." JCEM. 1035:1715-1744. Finding: Refer to urology if PSA rises >1.4 ng/mL above baseline. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness